Evidence map›Paper›PMID 25426554›Full record

ArticleOncotarget2015

Mutation of Vav1 adaptor region reveals a new oncogenic activation.

Lyra Razanadrakoto, Françoise Cormier, Vanessa Laurienté, Elisabetta Dondi, Laura Gardano, Shulamit Katzav, Lionel Guittat, Nadine Varin-Blank

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Targeting Rac and Cdc42 GEFs in Metastatic Cancer.Frontiers in cell and developmental biology · 2020
    Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Lyra RazanadrakotoINSERM, UMR 978, Bobigny, France.
Françoise CormierINSERM, UMR 1016, Institut Cochin, Paris, France.
Vanessa LaurientéINSERM, UMR 978, Bobigny, France.
Elisabetta DondiINSERM, UMR 978, Bobigny, France.
Laura GardanoINSERM, UMR 978, Bobigny, France.
Shulamit KatzavThe Hebrew University/ Hadassah Medical School, Jerusalem, Israel.
Lionel GuittatINSERM, UMR 978, Bobigny, France.
Nadine Varin-BlankINSERM, UMR 978, Bobigny, France.
Inserm · FRAssociation pour la Recherche en Physiologie de l’Environnement · FRHebrew University of Jerusalem · ILUniversité Paris Cité · FRUniversité Sorbonne Paris Nord · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vav family members function as remarkable scaffold proteins that exhibit both GDP/GTP exchange activity for Rho/Rac GTPases and numerous protein-protein interactions via three adaptor Src-homology domains. The exchange activity is under the unique regulation by phosphorylation of tyrosine residues hidden by intra-molecular interactions. Deletion of the autoinhibitory N-terminal region results in an oncogenic protein, onco-Vav, leading to a potent activation of Rac GTPases whereas the proto-oncogene barely leads to transformation. Substitution of conserved residues of the SH2-SH3 adaptor region in onco-Vav reverses oncogenicity. While a unique substitution D797N did not affect transformation induced by onco-Vav, we demonstrate that this single substitution leads to transformation in the Vav1 proto-oncogene highlighting the pivotal role of the adaptor region. Moreover, we identified the cell junction protein β-catenin as a new Vav1 interacting partner. We show that the oncogenicity of activated Vav1 proto-oncogene is associated with a non-degradative phosphorylation of β-catenin at residues important for its functions and its redistribution along the cell membrane in fibroblasts. In addition, a similar interaction is evidenced in epithelial lung cancer cells expressing ectopically Vav1. In these cells, Vav1 is also involved in the modulation of β-catenin phosphorylation. Altogether, our data highlight that only a single mutation in the proto-oncogene Vav1 enhances tumorigenicity.

Indexed as

MutationAnimalsAnthracenesAspartic Acidbeta CateninBlotting, WesternCell Line, TumorCell Transformation, NeoplasticFibroblastsHEK293 CellsHumansMAP Kinase Kinase 4MiceMice, NudeNIH 3T3 CellsPhosphorylationAnthracenesAspartic Acidbeta CateninMAP Kinase Kinase 4MAS1 protein, humanProto-Oncogene MasProto-Oncogene Proteins c-vavpyrazolanthroneVAV1 protein, human

Identifiers

PMID25426554
PMCPMC4385868
OpenAlexW1855240286

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.